Engel Law PLLC is investigating whether fair value to CinCor shareholders will result from the proposed sale of CinCor Pharma, Inc. (NASDAQ: CINC) to AstraZeneca for $26.00 per share in cash plus a non-tradable contingent value right of $10.00 per share in cash.
The Firm’s investigation concerns:
(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.